S095035 + TNG462
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
MTAP-deleted Solid Tumors
Conditions
MTAP-deleted Solid Tumors
Trial Timeline
Apr 29, 2024 → Oct 31, 2031
NCT ID
NCT06188702About S095035 + TNG462
S095035 + TNG462 is a phase 1/2 stage product being developed by Tango Therapeutics for MTAP-deleted Solid Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06188702. Target conditions include MTAP-deleted Solid Tumors.
Hype Score Breakdown
Clinical
9
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06188702 | Phase 1/2 | Recruiting |
Competing Products
3 competing products in MTAP-deleted Solid Tumors
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AMG 193 | Amgen | Phase 2 | 42 |
| BAY 3713372 | Bayer | Phase 1/2 | 36 |
| BG-89894 | BeOne Medicines | Phase 1 | 33 |